<--- Back to Details
First PageDocument Content
Myelofibrosis / Janus kinase inhibitor / Splenomegaly / Myeloproliferative neoplasm / Ruxolitinib / Medical diagnosis / Polycythemia vera
Date: 2015-09-20 08:20:56
Myelofibrosis
Janus kinase inhibitor
Splenomegaly
Myeloproliferative neoplasm
Ruxolitinib
Medical diagnosis
Polycythemia vera

HAEMATOLOGY AUDIT TEMPLATE

Add to Reading List

Source URL: www.bcshguidelines.com

Download Document from Source Website

File Size: 2,47 MB

Share Document on Facebook

Similar Documents

Myelofibrosis / Janus kinase inhibitor / Splenomegaly / Myeloproliferative neoplasm / Ruxolitinib / Medical diagnosis / Polycythemia vera

HAEMATOLOGY AUDIT TEMPLATE

DocID: 1pL02 - View Document

Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016

Needham & Company 15th Annual Healthcare Conference John Scarlett, M.D. President & CEO, Geron Corporation April 12, 2016

DocID: 1pn6V - View Document

1  Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62

1 Dr Jürgen Thiele Institute for Pathology University of Cologne Kerpener Str. 62

DocID: 1ohLr - View Document

Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard

Phase 2 trial of PRM-151, an anti-fibrotic agent, in patients with myelofibrosis: Stage 1 results Srdan Verstovsek1, Ruben Mesa2, Lynda Foltz3, Vikas Gupta4, John Mascarenhas5, Ellen Ritchie6, Ronald Hoffman5, Richard

DocID: 19YPO - View Document

Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

Novartis Pharmaceuticals Canada Inc. 385 Bouchard Blvd. Dorval, Quebec Canada H9S 1A9 www.novartis.ca

DocID: 19fx5 - View Document